Tigermed and Frontage Laboratories Complete Strategic Investment Agreement
Hangzhou Tigermed Consulting and Frontage Laboratories announced completion of the previously announced investment agreement
Hangzhou Tigermed Consulting and Frontage Laboratories announced completion of the previously announced investment agreement, following approval by the China Securities and Regulatory Commission. Tigermed, a provider of outsourced clinical development services across China and Asia Pacific regions to the pharmaceutical and medical device industries has acquired a majority position in the ownership of Frontage, a bioanalysis, preclinical studies, early phase clinical studies and product development services provider for biopharmaceutical organizations. The partnership establishes the presence of Tigermed's global clinical trial network. Frontage will continue to operate independently, and will retain its existing company name, management team and operations facilities.
Read the full release here.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
